Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer

Minami, Seigo; Ogata, Yoshitaka; Ihara, Satoshi; Yamamoto, Shuichi; Komuta, Kiyoshi

doi:10.2147/lctt.s142880

Cited by 29 publications

(57 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study also demonstrated that pretreatment mGPS and PNI are independent predictors of OS in patients with advanced SCLC [14]. In line with these studies, pretherapeutic elevated serum albumin, CRP, and LDH, decreased sodium, as well as a high mGPS and high PI were also significantly associated with reduced PFS in our study cohort.…”

Section: Discussionsupporting

confidence: 89%

“…Several studies have already identified pretherapeutic prognostic markers and scores to predict outcome in SCLC patients [7,8,9,10,11,12,13,14]. A recent study also demonstrated that pretreatment mGPS and PNI are independent predictors of OS in patients with advanced SCLC [14].…”

Section: Discussionmentioning

confidence: 99%

“…For about 30 years, lactate dehydrogenase (LDH) and serum albumin have been described to predict OS in SCLC [7,8,9]. Different markers and scores for acute inflammation, i.e., the neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP) levels, the modified Glasgow prognostic score (mGPS), the prognostic nutritional index (PNI), and the systemic immune-inflammation index (SII) have been associated with poor outcome in SCLC [10,11,12,13,14]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC

Kauffmann-Guerrero¹,

Kahnert²,

Syunyaeva³

et al. 2018

Oncol Res Treat

View full text Add to dashboard Cite

Background: Despite initial response to chemotherapy, the prognosis of small cell lung cancer (SCLC) patients is limited. Following first-line therapy, the strongest predictor of durable progression-free survival (PFS) is remission quality. Febrile neutropenia (FN) is a frequent complication after chemotherapy, and its prevention could improve treatment density and degree of remission. Patients and Methods: We retrospectively analyzed 39 SCLC patients treated at a German tertiary care lung cancer center between 2013 and 2016. We extracted data sets from electronic records and analyzed anthropometric data, pretherapeutic blood values, and prognostic scores. Discriminant analysis was performed to predict FN. Results: PFS after first-line chemotherapy was significantly shorter in patients with FN (p = 0.003). Pretherapeutic albumin (p = 0.019), C-reactive protein (CRP; p < 0.001), lactate dehydrogenase (p = 0.041), neutrophil-to-lymphocyte ratio (p = 0.009), prognostic nutritional index (p = 0.018), and Glasgow prognostic score (p < 0.001) were significantly associated with FN. CRP in combination with absolute neutrophil count is a strong predictor of FN (positive predictive value 79.8%). Conclusion: SCLC patients with FN after chemotherapy showed significantly reduced PFS. Prevention of FN may improve treatment results. We identified pretherapeutic markers which can predict FN risk. This simple and cost-effective method could serve to identify the need for preventive measures against FN (e.g., prophylactic antibiotic treatment or granulocyte colony stimulating factor administration).

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC

Kauffmann-Guerrero¹,

Kahnert²,

Syunyaeva³

et al. 2018

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Pembrolizumab was approved as the first-line regimen for a specific population of NSCLC by Japanese medical insurance in December 2016, and has been available in our hospital since March 2017. The methods, classifications and definitions of clinical profiles, creatinine clearance (Ccr), NLR, LMR, mGPS, response rate (RR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) followed those of our previous studies [ 15 , 16 ]. The data cutoff was December 31, 2017.…”

Section: Methodsmentioning

confidence: 99%

“…In various types of cancers, including advanced NSCLC, higher NLR [ 8 - 10 ], lower LMR [ 11 , 12 ] and Glasgow prognostic score (GPS) class 2 [ 13 , 14 ] are independent prognostic markers for shorter survival. Our previous studies also demonstrated that NLR for NSCLC with active EGFR mutation [ 15 ], LMR and mGPS for adenocarcinoma without any driver mutation, and mGPS for small cell lung carcinoma [ 16 ] were significant prognostic factors. However, it is not clear that these three prognostic markers are also useful for patients with advanced SCC.…”

Section: Introductionmentioning

confidence: 93%

Pretreatment Lymphocyte to Monocyte Ratio as a Prognostic Marker for Advanced Pulmonary Squamous Cell Carcinoma Treated With Chemotherapy

2018

Self Cite

View full text Add to dashboard Cite

BackgroundLower lymphocyte to monocyte ratio (LMR), higher neutrophil to lymphocyte ratio (NLR) and modified Glasgow prognostic score (mGPS) 2 have been demonstrated as independent prognostic markers for poor prognosis of advanced non-small cell lung cancer (NSCLC). However, little is known about these three markers as prognostic markers for a specific histological subset of NSCLC, squamous cell carcinoma (SCC). This study aimed to evaluate the prognostic significance of LMR, NLR and mGPS for advanced SCC.MethodsWe retrospectively collected 107 patients who met the following criteria: pathologically confirmed SCC, chemo-naive patients who had initiated first-line cytotoxic chemotherapy between September 2007 and February 2017 at our institution, and c-stage IIIB, IV or recurrence after curative-intent surgery or thoracic radiotherapy. In order to demonstrate these three markers as significant prognostic factors, we compared overall survival (OS) between two groups divided by LMR, NLR and mGPS 0 - 1 versus 2, and performed univariate and multivariate Cox proportional hazard analyses.ResultsGroups with low LMR (< 2.07) and high NLR (≥ 5.28) experienced shorter OS (LMR: 6.5 versus 15.6 months in median, P < 0.01; NLR: 8.2 versus 15.6 months, P < 0.01) than groups with high LMR (≥ 2.07) and low NLR (< 5.28). However, no significant difference was detected in OS between mGPS 0 - 1 and 2 (13.0 versus 13.7 months, P = 0.61). As significant poor prognostic factors, our multivariate Cox hazard analysis detected ECOG PS 2 - 4 (hazard ration (HR): 3.09, 95% confidence interval (CI): 1.77 - 5.40; P < 0.01) and LMR < 2.07 (HR: 0.39, 95% CI: 0.21 - 0.79; P < 0.01). However, NLR was not selected in the multivariate analysis.ConclusionLMR is an independent prognostic factor for advanced pulmonary SCC. Neither NLR nor mGPS is useful as prognostic factor for this histology. The optimal prognostic markers may differ from each subset of NSCLC.

show abstract

Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors

Pan

Voutsinas

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Background Little is known regarding associations between peripheral blood biomarkers (PBBMs) and survival, response, and toxicity in recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs). Methods In this single‐institution retrospective cohort study, a dataset of patients with R/M HNSCC treated with ICIs between 08/2012–03/2021 was established, including demographic and clinicopathologic characteristics. Pretreatment PBBMs were collected and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv5, objective response (ORR) by RECIST 1.1, overall survival (OS), and progression‐free survival (PFS). Multivariable models for each outcome were created using elastic net variable selection. Results Our study included 186 patients, with 51 (27%) demonstrating complete or partial response to immunotherapy. Multivariable models adjusted for ECOG performance status (PS), p16, and smoking demonstrated that pretreatment higher LDH and absolute neutrophils, as well as lower percent lymphocytes correlated with worse OS and PFS. Higher LDH and lower % lymphocytes also correlated with worse ORR. Conclusions In the largest study to date examining PBBMs in ICI‐treated R/M HNSCCs, our variable selection method revealed PBBMs prognostic for survival and response to immunotherapy. These biomarkers warrant further investigation in a prospective study along with validation with CPS biomarker.

show abstract

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer

Cited by 29 publications

References 14 publications

Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC

Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC

Pretreatment Lymphocyte to Monocyte Ratio as a Prognostic Marker for Advanced Pulmonary Squamous Cell Carcinoma Treated With Chemotherapy

Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors

Contact Info

Product

Resources

About